{
  "resourceType": "MedicationStatement",
  "id": "medication-bevacizumab",
  "status": "active",
  "medicationCodeableConcept": {
    "coding": [
      {
        "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
        "code": "149574",
        "display": "Bevacizumab"
      }
    ],
    "text": "Bevacizumab (Avastin)"
  },
  "subject": {
    "reference": "Patient/patient-001",
    "display": "Jane Marie TestPatient"
  },
  "effectivePeriod": {
    "start": "2023-03-15"
  },
  "dateAsserted": "2024-12-01",
  "informationSource": {
    "display": "Dr. Oncologist"
  },
  "reasonReference": [
    {
      "reference": "Condition/condition-ovarian-cancer"
    }
  ],
  "note": [
    {
      "text": "Second-line treatment for platinum-resistant disease. Currently ongoing. Clinical trial evaluating bevacizumab + PARP inhibitor combination."
    }
  ],
  "dosage": [
    {
      "text": "15 mg/kg IV every 21 days",
      "timing": {
        "repeat": {
          "frequency": 1,
          "period": 21,
          "periodUnit": "d"
        }
      },
      "route": {
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "47625008",
            "display": "Intravenous route"
          }
        ]
      }
    }
  ]
}
